Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ligand in various RA populations and other inflammatory diseases. This consensus document informs on interference with the IL-6 pathway based on evidence and expert opinion.

Smolen, J., Schoels, M., Nishimoto, N., Breedveld, F., Burmester, G., Dougados, M., Emery, P., Ferraccioli, G., Gabay, C., Gibofsky, A., Gomez Reino, J., Jones, G., Kvien, T., Murakami, M., Betteridge, N., Bingham, C., Bykerk, V., Choy, E., Combe, B., Cutolo, M., Graninger, W., Lanas, A., Martin Mola, E., Montecucco, C., Ostergaard, M., Pavelka, K., Rubbert Roth, A., Sattar, N., Scholte Voshaar, M., Tanaka, Y., Trauner, M., Valentini, G., Winthrop, K., De Wit, M., Van Der Heijde, D., Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions, <<EARD>>, 2013; 72 (4): 482-492. [doi:10.1136/annrheumdis-2012-202469] [http://hdl.handle.net/10807/41188]

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

Ferraccioli, Gianfranco;
2013

Abstract

Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ligand in various RA populations and other inflammatory diseases. This consensus document informs on interference with the IL-6 pathway based on evidence and expert opinion.
Inglese
Smolen, J., Schoels, M., Nishimoto, N., Breedveld, F., Burmester, G., Dougados, M., Emery, P., Ferraccioli, G., Gabay, C., Gibofsky, A., Gomez Reino, J., Jones, G., Kvien, T., Murakami, M., Betteridge, N., Bingham, C., Bykerk, V., Choy, E., Combe, B., Cutolo, M., Graninger, W., Lanas, A., Martin Mola, E., Montecucco, C., Ostergaard, M., Pavelka, K., Rubbert Roth, A., Sattar, N., Scholte Voshaar, M., Tanaka, Y., Trauner, M., Valentini, G., Winthrop, K., De Wit, M., Van Der Heijde, D., Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions, <<EARD>>, 2013; 72 (4): 482-492. [doi:10.1136/annrheumdis-2012-202469] [http://hdl.handle.net/10807/41188]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/41188
Citazioni
  • ???jsp.display-item.citation.pmc??? 30
  • Scopus 99
  • ???jsp.display-item.citation.isi??? 87
social impact